

|                              |                                                                                                                                                                                 |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Codes ATC: J01GB06           |                                                                                                                                                                                 |
| Indication                   | Inflammatory and other diseases of prostate <span>Code ICD11: GA91.Z</span>                                                                                                     |
| INN                          | Amikacin                                                                                                                                                                        |
| Type de médicament           | Chemical agent                                                                                                                                                                  |
| Groupe d'antibiotiques       | <span>A ACCESS</span>                                                                                                                                                           |
| Type de liste                | Liste de base                                                                                                                                                                   |
| Formulations                 | Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)                                                                                          |
| Historique des statuts LME   | Ajouté pour la première fois en 2017 (TRS 1006)<br>Modifié en 2023 (TRS 1049)                                                                                                   |
| Sexe                         | Mâle                                                                                                                                                                            |
| Âge                          | Adolescents et adultes                                                                                                                                                          |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique                                                                                                                             |
| Renseignements sur le brevet | Patents have expired in most jurisdictions<br>Lire la suite <a href="#">sur les brevets.</a>  |
| Wikipédia                    | <a href="#">Amikacin</a>                                                                     |
| DrugBank                     | <a href="#">Amikacin</a>                                                                     |

Recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

Recommandations de la LME : Inflammatory and other diseases of prostate

Premier choix

Second choix

MILD TO MODERATE

ciprofloxacin

ceftriaxone

cefotaxime

SEVERE

ceftriaxone

co-prescrire avec [amikacin](#)

cefotaxime

co-prescrire avec [amikacin](#)

